查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1864102

按技術類型、應用、治療領域、最終用戶、產品類型和模式分類的能量治療方法市場—2025-2032年全球預測

Energy-Based Therapeutics Market by Technology Type, Application, Therapeutic Area, End User, Product Type, Mode - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，能量治療方法市場將成長至 131.1 億美元，複合年成長率為 7.61%。

關鍵市場統計數據
基準年 2024 72.8億美元
預計年份：2025年 78.5億美元
預測年份 2032 131.1億美元
複合年成長率 (%) 7.61%

本書清晰而富有遠見地介紹了技術創新、臨床需求和監管演變如何重塑各專科領域對能量治療方法的採用。

過去十年間，能量治療方法已從小眾手術工具發展成為多個臨床專科的基礎平台。設備工程、影像整合和手術流程的創新，拓展了利用聚焦能量進行組織診斷、修復、消融和再生等治療方法的臨床應用範圍。因此，臨床醫生和醫療系統正在重新調整治療流程，以抓住機遇，縮短手術時間、減少住院時間，並將治療轉移到門診進行。

技術融合、服務主導的商業化和供應鏈重組將如何從根本上改變能量治療方法的交付和應用

醫療格局正經歷一場變革性的轉變，其驅動力來自三個相互關聯的因素：技術融合、醫療服務體系重組、實證商業化。設備小型化、影像導引標靶和軟體控制技術的進步，使得治療更加精準且微創。這種融合降低了門診實施的技術門檻，將以往需要在醫院進行的治療轉移到了診所和居家醫療環境中。

評估關稅引發的成本壓力對全球能源相關醫療設備供應鏈的更廣泛影響（營運、採購和產品開發）。

政策變化和關稅有可能在全球醫療設備供應鏈中造成重大摩擦，而近期關稅措施的累積影響正在重塑採購、製造和定價格局。醫療設備零件和成品進口成本的上升正促使原始設備製造商 (OEM) 重新評估供應商契約，加快替代供應商的資質認證，並在許多情況下建立區域製造地，以降低跨境關稅波動帶來的風險。這些策略轉變與對高品質零件和特殊材料的持續需求同時發生，使得快速更換供應商變得更加複雜。

基於深度細分的洞察，揭示技術類型、臨床應用、治療領域、最終用戶、產品類型和模式的交匯點，從而塑造策略重點。

了解能量治療方法中臨床需求、投資和創新集中方向的關鍵在於掌握細分市場的趨勢。從技術層面來看，該市場涵蓋冷凍療法、電刺激療法、高強度聚焦超音波、雷射（包括二氧化碳雷射、二極體雷射、鉺：YAG雷射和釹：YAG雷射）、磁場療法、微波療法、雙極、單極和POLA射頻療法以及超音波。每項技術在資本密集度、耗材需求和臨床證據要求方面均有所不同，其中雷射和射頻平台由於其精準性和多樣化的施用器生態系統，通常價格分佈更高。

不同區域的法規結構、商業化路徑和製造生態系統如何創造差異化的機會和實施需求

區域趨勢將對能量治療方法開發商的監管策略、商業化時間表和生產重點產生重大影響。在美洲，由醫院、門診中心和專科診所組成的成熟生態系統，在完善的監管路徑和對臨床證據的高度重視的支持下，正推動著那些展現出明確治療效果的技術的應用。採購行為傾向於選擇能夠簡化採購流程並提供培訓和服務支援的捆綁式解決方案，而區域生產能力仍集中在能夠支援產品快速改進的成熟產業叢集周圍。

對成熟企業、專業創新者和跨學科夥伴關係如何塑造競爭、差異化和商業化路徑的實用評估

能量治療方法領域的競爭格局呈現出多元化的特點，既有成熟的醫療設備公司，也有專業系統製造商，還有專注於特定臨床應用或底層技術的敏捷型Start-Ups。現有企業憑藉其豐富的產品系列和成熟的分銷網路，通常將設備與耗材和服務合約捆綁銷售。同時，敏捷的新興參與企業則透過特定的臨床證據、低資本密集度或創新的臨床工作流程脫穎而出。隨著企業將療效追蹤和遠端監測納入其價值提案，設備製造商與軟體/分析提供者之間的合作也日益普遍。

領導者可以採取的切實可行的策略重點和有效手段，以降低風險、加速推廣並建立永續的商業性優勢。

產業領導者應優先採取一系列策略行動，加速產品在短期內的普及，同時保障消費者的選擇權。首先，企業應實現供應商網路多元化，並投資於模組化產品架構，以降低關稅和供應鏈風險，同時保持針對不同監管市場的設計彈性。其次，從產品開發的早期階段開始，透過務實的臨床試驗和基於註冊的研究，收集臨床證據，對於確保獲得有利的報銷和支持基本契約談判至關重要。第三，企業應採用整合的商業模式，將設備銷售與耗材計畫和軟體服務結合，以創造持續收入並提高客戶維繫留存率。

一個穩健的混合方法研究框架，結合專家訪談、監管和臨床證據審查以及情境分析，以得出可靠的策略見解。

本執行摘要的研究綜合採用了一種多方法論，將定性研究結果與已發表的監管和臨床證據進行三角驗證。主要研究包括對臨床醫生、採購主管和高階相關人員進行結構化訪談，以了解實際應用中的推廣促進因素、流程和採購標準。次要研究涵蓋了同行評審的臨床文獻、監管文件、專利概況和臨床試驗註冊資訊，以驗證技術性能檢驗並找出證據缺口。

這份簡明扼要的策略要點總結強調了基於證據的商業化、模組化產品設計以及增強區域執行力，以實現持續的價值創造。

總之，能量治療方法正處於一個轉捩點。技術進步、醫療服務模式的轉變以及不斷變化的商業性需求相互交織，為改善患者療效和創建新的經營模式創造了重大機會。在此環境下取得成功，取決於能否將嚴謹的臨床證據與靈活的商業策略相結合，以滿足不同的終端用戶需求、適應區域監管環境並應對供應鏈的實際情況。能夠提供兼具清晰的經濟和臨床價值，同時又能降低流程複雜性的整合解決方案的公司，將最有可能獲得持續的市場認可。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 在老齡化社會中擴大家用光生物調節設備在慢性疼痛管理的應用
  • 將人工智慧驅動的治療計畫整合到高強度聚焦超音波腫瘤治療中
  • 射頻微針設備在微創美容緊膚療程的應用​​日益廣泛
  • 開發用於治療特定肌肉骨骼損傷的攜帶式低強度衝擊波治療平台
  • 監管核准和報銷政策的變化推動了非侵入式塑形解決方案的成長
  • 一種用於協同皮膚治療的雷射和射頻聯合平台的出現
  • 用於非侵入性神經治療的超音波導引神經調控裝置的創新

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依技術類型分類的能量治療方法市場

  • 冷凍療法
  • 電刺激
  • 高強度聚焦超音波
  • 雷射
    • 二氧化碳雷射
    • 二極體雷射
    • 鉺YAG雷射
    • Nd:YAG雷射
  • 磁療
  • 微波療法
  • 高頻
    • 雙極
    • 單極
    • 多極
  • 超音波

9. 按應用分類的能量治療方法市場

  • 美麗
    • 塑形
    • 除毛
    • 疤痕治療
    • 皮膚修復
      • 皮膚緊緻
      • 分段式表面置換
      • 光子嫩膚
    • 去除紋身
    • 減少皺紋
  • 心血管系統
    • 血管成形術
    • 心律不整治療
    • 血管外科
  • 腫瘤學
    • 乳癌
    • 肝癌
    • 攝護腺癌
  • 眼科
    • 白內障治療
    • 青光眼治療
    • 視網膜治療
  • 疼痛管理
    • 腰痛
    • 關節疼痛
    • 肌肉骨骼疼痛
    • 神經病變疼痛
  • 物理治療
    • 肌肉刺激
    • 復原
    • 腫脹減輕
    • 創傷治療
  • 外科手術
    • 心血管外科
    • 眼科手術
    • 止血
    • 組織切除
    • 腫瘤切除

10. 按治療領域分類的能量治療方法市場

  • 心臟病學
  • 皮膚科
  • 神經病學
  • 腫瘤學
  • 整形外科

第11章：按最終用戶分類的能量治療方法市場

  • 門診手術中心
  • 皮膚科診所
  • 居家醫療環境
  • 醫院
  • 物理治療中心

第12章：按產品類型分類的能量治療方法市場

  • 配件和耗材
  • 裝置
  • 服務和軟體

13. 按模式分類的能量治療方法市場

  • 侵入性
  • 微創
  • 非侵入性

14. 各地區能量治療方法市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章：按組別分類的能量治療方法市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

16. 各國能量治療方法市場概況

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • AbbVie Inc.
    • Hologic, Inc.
    • Lumenis Ltd.
    • Cutera, Inc.
    • InMode Ltd.
    • Sisram Medical Ltd.
    • Bausch Health Companies Inc.
    • Venus Concept Inc.
    • Candela Corporation
    • Strata Skin Sciences, Inc.
Product Code: MRR-BB4648AFF39A

The Energy-Based Therapeutics Market is projected to grow by USD 13.11 billion at a CAGR of 7.61% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 7.28 billion
Estimated Year [2025] USD 7.85 billion
Forecast Year [2032] USD 13.11 billion
CAGR (%) 7.61%

A clear, forward-looking primer on how technological innovation, clinical demand, and regulatory evolution are reshaping energy-based therapeutic adoption across specialties

The past decade has seen energy-based therapeutics transition from niche procedural tools into foundational platforms across multiple clinical specialties. Innovations in device engineering, imaging integration, and procedure workflows have expanded the clinical footprint of therapies that use focused energy to diagnose, modulate, ablate, or regenerate tissue. As a result, clinicians and health systems are recalibrating treatment algorithms to take advantage of shorter procedure times, reduced hospitalization, and opportunities to shift care toward ambulatory and outpatient settings.

Regulatory pathways and reimbursement environments are evolving in parallel, shaping adoption curves and influencing design priorities for new product entrants. Manufacturers now face a dual imperative: demonstrating robust clinical evidence that substantiates safety and long-term outcomes while also articulating clear economic value propositions for payors and providers. Concurrently, patient expectations for less invasive, more precise, and cosmetically favorable interventions are accelerating demand across aesthetic and therapeutic indications. Taken together, these forces are reorienting investment, partnership, and commercialization strategies across the ecosystem of device developers, service providers, and clinical adopters.

How technological convergence, service-led commercialization, and supply chain realignment are driving a fundamental shift in energy-based therapeutics delivery and adoption

The landscape is undergoing transformative shifts driven by three intersecting vectors: technological convergence, care delivery reorganization, and evidence-based commercialization. Advances in device miniaturization, imaging-guided targeting, and software-enabled controls are enabling treatments that are simultaneously more precise and less invasive. This convergence has lowered technical barriers to adoption in outpatient and ambulatory settings, allowing procedures that once required hospital infrastructure to migrate into clinics and homecare environments.

Simultaneously, the commercialization model is shifting from a purely product-centric approach to integrated solutions that bundle equipment with consumables, digital services, and outcome-monitoring software. Value-based reimbursement models and growing scrutiny on total cost of care are pressuring stakeholders to demonstrate longitudinal patient benefits, not just procedural efficacy. As a result, companies that can pair clinical evidence with service-oriented delivery models and robust real-world data capture are positioned to gain preferential adoption. Finally, external pressures such as supply chain volatility and geopolitical shifts are accelerating near-shoring and supplier diversification strategies, prompting manufacturers to rethink component sourcing and lifecycle management.

Assessing the broad operational, procurement, and product development implications of tariff-driven cost pressures on global energy-based device supply chains

Policy changes and tariff implementations can create material friction across a global medical device supply chain, and the cumulative impact of recent tariff actions is reshaping procurement, manufacturing, and pricing dynamics. Increased import costs for device components and finished goods have prompted original equipment manufacturers to revisit supplier contracts, accelerate qualification of alternative vendors, and in many cases to explore regional manufacturing footprints that reduce exposure to cross-border tariff volatility. These strategic shifts are occurring alongside continued demand for high-quality components and specialized materials, which complicates rapid supplier substitution.

For hospitals, clinics, and ambulatory surgical centers, the direct effect is often higher capital outlay or incremental pricing pressure on consumables, which in turn influences purchasing prioritization and the relative attractiveness of bundled service agreements. Meanwhile, developers face an elevated cost base for R&D and prototyping when critical components become more expensive or less reliably available. Over time, tariff-driven cost pressures can influence product roadmaps by elevating the importance of modularity, component standardization, and software-driven feature differentiation that reduces reliance on high-cost hardware. To mitigate these impacts, strategic responses observed across the industry include diversified supplier networks, near-shore manufacturing investments, and contractual hedging strategies that align stocking policies with forecasted demand and regulatory timelines.

Deep segmentation-driven insights revealing where technology types, clinical applications, therapeutic areas, end users, product types, and modes intersect to shape strategic priorities

Segment-specific dynamics are central to understanding where clinical demand, investment, and innovation are concentrated across the energy-based therapeutics landscape. On the technology front, the market encompasses Cryotherapy, Electrical Stimulation, High Intensity Focused Ultrasound, Laser-including CO2 Laser, Diode Laser, Erbium YAG Laser, and Nd:YAG Laser-Magnetic Field Therapy, Microwave Therapy, Radio Frequency across Bipolar, Monopolar, and Multipolar configurations, and Ultrasound. Each technological family has distinct capital intensity, consumable requirements, and clinical evidence expectations, with lasers and radio frequency platforms often commanding premium pricing due to precision capabilities and diverse applicator ecosystems.

Application-driven segmentation reveals differentiated adoption curves and clinical priorities. Aesthetics applications such as Body Contouring, Hair Removal, Scar Treatment, Skin Rejuvenation-spanning Dermal Tightening, Fractional Resurfacing, and Photofacial-Tattoo Removal, and Wrinkle Reduction are driving rapid commercial uptake in clinic and ambulatory settings where patient demand and procedural revenue are high. Cardiovascular applications including Angioplasty, Arrhythmia Treatment, and Vascular Surgery require rigorous regulatory and clinical validation but offer substantial clinical impact. Oncology applications focused on Breast Cancer, Liver Cancer, and Prostate Cancer demand integration with imaging and multidisciplinary care pathways, while Ophthalmology applications from Cataract Treatment to Glaucoma Treatment and Retinal Therapies emphasize miniaturization and precision. Pain Management covering Back Pain, Joint Pain, Musculoskeletal Pain, and Neuropathic Pain and Physiotherapy fields such as Muscle Stimulation, Rehabilitation, Swelling Reduction, and Wound Healing often favor devices that balance efficacy with low procedural complexity. Surgical indications that include Cardiovascular Surgery, Eye Surgery, Hemostasis, Tissue Ablation, and Tumor Resection place a premium on device reliability and intraoperative ergonomics.

Therapeutic area distinctions-Cardiology, Dermatology, Neurology, Oncology, and Orthopedics-inform clinical trial design and commercial access strategies, while end-user diversity spanning Ambulatory Surgical Centers, Dermatology Clinics, Homecare Settings, Hospitals, and Physiotherapy Centers drives differentiated service and training requirements. Product-level segmentation into Accessories & Consumables, Equipment, and Services & Software underscores the evolving business models where recurring consumables and outcome-monitoring software can create sustained revenue streams. Mode of delivery-Invasive, Minimally Invasive, and Non Invasive-continues to shape regulatory classification, patient recovery expectations, and purchaser criteria. By synthesizing these segmentation layers, stakeholders can prioritize investments where clinical need, reimbursement potential, and operational feasibility converge, tailoring product roadmaps and commercial propositions to the nuances of each segment.

How distinct regulatory frameworks, commercialization pathways, and manufacturing ecosystems across major global regions create differentiated opportunities and execution demands

Regional dynamics significantly influence regulatory strategy, commercialization timelines, and manufacturing priorities for energy-based therapeutic developers. In the Americas, a mature ecosystem of hospitals, ambulatory centers, and specialist clinics is supported by a well-established regulatory pathway and a strong emphasis on clinical evidence, which facilitates adoption for technologies that demonstrate clear outcome improvements. Purchasing behavior tends to favor bundled solutions that simplify procurement and provide training and service support, and regional manufacturing capacity remains concentrated around established clusters that support rapid product iteration.

Across Europe, the Middle East & Africa, regulatory diversity creates both complexity and opportunity. European markets are influenced by harmonized regulatory frameworks and evolving medical device requirements that drive rigorous conformity and post-market surveillance expectations. In many Middle Eastern and African markets, adoption is uneven, with pockets of rapid modernization in urban centers and a growing appetite for devices suited to outpatient or clinic-based care. The Asia-Pacific region exhibits heterogeneity driven by strong manufacturing capabilities, rapidly expanding private healthcare networks, and a growing prevalence of aesthetic and elective procedures. Local R&D centers and contract manufacturers in the region accelerate cost-competitive production, while rising patient demand in urban centers creates sizable opportunities for scalable, lower-cost solutions. Each regional bloc therefore requires distinct go-to-market approaches, regulatory roadmaps, and partnership strategies to align with localized payer models, clinical practice patterns, and supply chain realities.

A pragmatic assessment of how established firms, focused innovators, and cross-disciplinary partnerships are shaping competition, differentiation, and commercialization paths

Competitive dynamics in energy-based therapeutics are characterized by a mix of established medical device firms, specialized system manufacturers, and agile start-ups that often focus on niche clinical applications or enabling technologies. Incumbents frequently leverage broad product portfolios and established distribution networks to bundle equipment with consumables and service contracts, while nimble entrants differentiate on targeted clinical evidence, lower capital intensity, or novel clinical workflows. Partnerships between device makers and software or analytics providers are increasingly prevalent as companies seek to embed outcome tracking and remote monitoring into their value propositions.

Intellectual property, regulatory approvals, and high-quality clinical data remain key barriers to market entry. Therefore, strategic activity often centers on acquiring complementary technologies, forging clinical collaborations, and investing in post-market studies that reinforce safety and long-term efficacy claims. Companies that effectively align product design with end-user operational needs-optimizing ergonomics for surgeons, workflow integration for clinics, and remote support capabilities for homecare-are able to accelerate adoption and create defensible positions. Finally, service-led models and consumable-driven revenue streams are becoming critical levers for sustaining commercial momentum once clinical acceptance is achieved.

Actionable strategic priorities and pragmatic execution levers that leaders can deploy to mitigate risk, accelerate adoption, and build durable commercial advantage

Industry leaders should prioritize a set of strategic actions that preserve optionality while accelerating near-term adoption. First, companies should diversify supplier networks and invest in modular product architectures to reduce tariff and supply chain exposure while preserving design flexibility for different regulatory markets. Second, embedding clinical evidence generation into early product development-through pragmatic trials and registry-based studies-will be essential to secure favorable reimbursement and to support value-based contracting discussions. Third, firms should adopt integrated commercial models that combine equipment sales with consumable programs and software-enabled services to create recurring revenue and improve customer retention.

Additionally, targeted regional strategies will be vital: prioritize high-value clinical indications and geographies with clear regulatory pathways and reimbursement readiness while deploying scalable rollouts in markets with strong outpatient and private clinic penetration. Leaders should also invest in digital ecosystems that enable remote monitoring, outcome measurement, and telehealth-enabled follow-up, thereby enhancing the overall patient experience and strengthening payer conversations. Finally, organizational capability-building-focused on cross-functional regulatory expertise, clinical affairs, and health economics-will accelerate navigation of complex approval pathways and support sustainable market access. By pursuing these coordinated actions, companies can reduce execution risk while maximizing the commercial impact of new product introductions.

A robust mixed-methods research framework combining expert interviews, regulatory and clinical evidence review, and scenario analysis to produce defensible strategic insights

The research synthesis underpinning this executive summary integrates a multi-method approach designed to triangulate qualitative insights with publicly available regulatory and clinical evidence. Primary research included structured interviews with clinicians, procurement leaders, and executive stakeholders to capture real-world adoption drivers, procedural workflows, and purchasing criteria. Secondary analysis encompassed peer-reviewed clinical literature, regulatory filings, patent landscapes, and clinical trial registries to validate technology performance claims and to map evidence gaps.

Data synthesis techniques included thematic analysis of expert interviews, comparative review of regulatory frameworks across major geographies, and scenario-based evaluation of supply chain and tariff impacts. Where direct data were limited, findings were corroborated through cross-validation with clinician advisory panels and simulation of commercial adoption pathways. Quality controls included source triangulation and independent review of clinical interpretations to ensure robustness. Limitations of the methodology are acknowledged, including variability in near-term policy changes and regional reimbursement heterogeneity, and recommendations emphasize adaptive strategies that remain robust across plausible regulatory and market scenarios.

A concise synthesis of strategic takeaways emphasizing evidence-led commercialization, modular product design, and resilient regional execution to capture lasting value

In conclusion, energy-based therapeutics stand at an inflection point where technological advancement, shifting care delivery models, and evolving commercial imperatives converge to create meaningful opportunities for improved patient outcomes and new business models. Success in this environment will hinge on the ability to couple rigorous clinical evidence with flexible commercial strategies that address diverse end-user needs, regional regulatory landscapes, and supply chain realities. Those who can deliver integrated solutions that reduce procedural complexity while demonstrating clear economic and clinical value will be best positioned to capture sustained adoption.

Looking ahead, manufacturers and investors should remain focused on modular product design, evidence-driven market entry, and service-oriented revenue models. Coordinated investments in regional manufacturing resilience, strategic partnerships, and digital health capabilities will mitigate external risks and amplify product differentiation. The path forward rewards strategic patience combined with decisive, evidence-backed market action.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Expansion of home-use photobiomodulation devices for chronic pain management in aging populations
  • 5.2. Integration of AI-driven treatment planning in high-intensity focused ultrasound oncology therapies
  • 5.3. Rising adoption of radiofrequency microneedling devices for minimally invasive aesthetic skin tightening
  • 5.4. Development of portable low-intensity shockwave therapy platforms for targeted musculoskeletal injuries
  • 5.5. Regulatory approval and reimbursement changes driving growth in noninvasive body contouring solutions
  • 5.6. Emergence of combined laser and radiofrequency platforms for synergistic dermatological treatments
  • 5.7. Innovation in ultrasound-guided neuromodulation devices for noninvasive neurological disorder interventions

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Energy-Based Therapeutics Market, by Technology Type

  • 8.1. Cryotherapy
  • 8.2. Electrical Stimulation
  • 8.3. High Intensity Focused Ultrasound
  • 8.4. Laser
    • 8.4.1. CO2 Laser
    • 8.4.2. Diode Laser
    • 8.4.3. Erbium YAG Laser
    • 8.4.4. Nd:YAG Laser
  • 8.5. Magnetic Field Therapy
  • 8.6. Microwave Therapy
  • 8.7. Radio Frequency
    • 8.7.1. Bipolar
    • 8.7.2. Monopolar
    • 8.7.3. Multipolar
  • 8.8. Ultrasound

9. Energy-Based Therapeutics Market, by Application

  • 9.1. Aesthetics
    • 9.1.1. Body Contouring
    • 9.1.2. Hair Removal
    • 9.1.3. Scar Treatment
    • 9.1.4. Skin Rejuvenation
      • 9.1.4.1. Dermal Tightening
      • 9.1.4.2. Fractional Resurfacing
      • 9.1.4.3. Photofacial
    • 9.1.5. Tattoo Removal
    • 9.1.6. Wrinkle Reduction
  • 9.2. Cardiovascular
    • 9.2.1. Angioplasty
    • 9.2.2. Arrhythmia Treatment
    • 9.2.3. Vascular Surgery
  • 9.3. Oncology
    • 9.3.1. Breast Cancer
    • 9.3.2. Liver Cancer
    • 9.3.3. Prostate Cancer
  • 9.4. Ophthalmology
    • 9.4.1. Cataract Treatment
    • 9.4.2. Glaucoma Treatment
    • 9.4.3. Retinal Therapies
  • 9.5. Pain Management
    • 9.5.1. Back Pain
    • 9.5.2. Joint Pain
    • 9.5.3. Musculoskeletal Pain
    • 9.5.4. Neuropathic Pain
  • 9.6. Physiotherapy
    • 9.6.1. Muscle Stimulation
    • 9.6.2. Rehabilitation
    • 9.6.3. Swelling Reduction
    • 9.6.4. Wound Healing
  • 9.7. Surgical
    • 9.7.1. Cardiovascular Surgery
    • 9.7.2. Eye Surgery
    • 9.7.3. Hemostasis
    • 9.7.4. Tissue Ablation
    • 9.7.5. Tumor Resection

10. Energy-Based Therapeutics Market, by Therapeutic Area

  • 10.1. Cardiology
  • 10.2. Dermatology
  • 10.3. Neurology
  • 10.4. Oncology
  • 10.5. Orthopedics

11. Energy-Based Therapeutics Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Dermatology Clinics
  • 11.3. Homecare Settings
  • 11.4. Hospitals
  • 11.5. Physiotherapy Centers

12. Energy-Based Therapeutics Market, by Product Type

  • 12.1. Accessories & Consumables
  • 12.2. Equipment
  • 12.3. Services & Software

13. Energy-Based Therapeutics Market, by Mode

  • 13.1. Invasive
  • 13.2. Minimally Invasive
  • 13.3. Non Invasive

14. Energy-Based Therapeutics Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Energy-Based Therapeutics Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Energy-Based Therapeutics Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. AbbVie Inc.
    • 17.3.2. Hologic, Inc.
    • 17.3.3. Lumenis Ltd.
    • 17.3.4. Cutera, Inc.
    • 17.3.5. InMode Ltd.
    • 17.3.6. Sisram Medical Ltd.
    • 17.3.7. Bausch Health Companies Inc.
    • 17.3.8. Venus Concept Inc.
    • 17.3.9. Candela Corporation
    • 17.3.10. Strata Skin Sciences, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY TECHNOLOGY TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY TECHNOLOGY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MODE, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MODE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS ENERGY-BASED THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA ENERGY-BASED THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA ENERGY-BASED THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ENERGY-BASED THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE ENERGY-BASED THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST ENERGY-BASED THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA ENERGY-BASED THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC ENERGY-BASED THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN ENERGY-BASED THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC ENERGY-BASED THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION ENERGY-BASED THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS ENERGY-BASED THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 ENERGY-BASED THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO ENERGY-BASED THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. ENERGY-BASED THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. ENERGY-BASED THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ENERGY-BASED THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY CRYOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY CRYOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY CRYOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY CRYOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY CRYOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY CRYOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ELECTRICAL STIMULATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ELECTRICAL STIMULATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ELECTRICAL STIMULATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ELECTRICAL STIMULATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ELECTRICAL STIMULATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ELECTRICAL STIMULATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY HIGH INTENSITY FOCUSED ULTRASOUND, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY HIGH INTENSITY FOCUSED ULTRASOUND, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY HIGH INTENSITY FOCUSED ULTRASOUND, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY HIGH INTENSITY FOCUSED ULTRASOUND, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY HIGH INTENSITY FOCUSED ULTRASOUND, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY HIGH INTENSITY FOCUSED ULTRASOUND, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY LASER, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY LASER, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY LASER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY LASER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY LASER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY LASER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY LASER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY LASER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY CO2 LASER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY CO2 LASER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY CO2 LASER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY CO2 LASER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY CO2 LASER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY CO2 LASER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY DIODE LASER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY DIODE LASER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY DIODE LASER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY DIODE LASER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY DIODE LASER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY DIODE LASER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ERBIUM YAG LASER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ERBIUM YAG LASER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ERBIUM YAG LASER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ERBIUM YAG LASER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ERBIUM YAG LASER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ERBIUM YAG LASER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ND:YAG LASER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ND:YAG LASER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ND:YAG LASER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ND:YAG LASER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ND:YAG LASER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ND:YAG LASER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MAGNETIC FIELD THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MAGNETIC FIELD THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MAGNETIC FIELD THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MAGNETIC FIELD THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MAGNETIC FIELD THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MAGNETIC FIELD THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MICROWAVE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MICROWAVE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MICROWAVE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MICROWAVE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MICROWAVE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MICROWAVE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY RADIO FREQUENCY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY RADIO FREQUENCY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY RADIO FREQUENCY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY RADIO FREQUENCY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY RADIO FREQUENCY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY RADIO FREQUENCY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY RADIO FREQUENCY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY RADIO FREQUENCY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY BIPOLAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY BIPOLAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY BIPOLAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY BIPOLAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY BIPOLAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY BIPOLAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MONOPOLAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MONOPOLAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MONOPOLAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MONOPOLAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MONOPOLAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MONOPOLAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MULTIPOLAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MULTIPOLAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MULTIPOLAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MULTIPOLAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MULTIPOLAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MULTIPOLAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ULTRASOUND, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ULTRASOUND, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ULTRASOUND, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY AESTHETICS, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY AESTHETICS, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY AESTHETICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY AESTHETICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY AESTHETICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY AESTHETICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY AESTHETICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY AESTHETICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY BODY CONTOURING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY BODY CONTOURING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY BODY CONTOURING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY BODY CONTOURING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY BODY CONTOURING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY BODY CONTOURING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY HAIR REMOVAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY HAIR REMOVAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY HAIR REMOVAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY HAIR REMOVAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY HAIR REMOVAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY HAIR REMOVAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY SCAR TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY SCAR TREATMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY SCAR TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY SCAR TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY SCAR TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY SCAR TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY SKIN REJUVENATION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY SKIN REJUVENATION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY SKIN REJUVENATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY SKIN REJUVENATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY SKIN REJUVENATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY SKIN REJUVENATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY SKIN REJUVENATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY SKIN REJUVENATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY DERMAL TIGHTENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY DERMAL TIGHTENING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY DERMAL TIGHTENING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY DERMAL TIGHTENING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY DERMAL TIGHTENING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY DERMAL TIGHTENING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY FRACTIONAL RESURFACING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY FRACTIONAL RESURFACING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY FRACTIONAL RESURFACING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY FRACTIONAL RESURFACING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY FRACTIONAL RESURFACING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY FRACTIONAL RESURFACING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PHOTOFACIAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PHOTOFACIAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PHOTOFACIAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PHOTOFACIAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PHOTOFACIAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PHOTOFACIAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY TATTOO REMOVAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY TATTOO REMOVAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY TATTOO REMOVAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY TATTOO REMOVAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY TATTOO REMOVAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY TATTOO REMOVAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY WRINKLE REDUCTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY WRINKLE REDUCTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY WRINKLE REDUCTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY WRINKLE REDUCTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY WRINKLE REDUCTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY WRINKLE REDUCTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ANGIOPLASTY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ANGIOPLASTY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ANGIOPLASTY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ANGIOPLASTY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ANGIOPLASTY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ANGIOPLASTY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ARRHYTHMIA TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ARRHYTHMIA TREATMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ARRHYTHMIA TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ARRHYTHMIA TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ARRHYTHMIA TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ARRHYTHMIA TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY VASCULAR SURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY VASCULAR SURGERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY VASCULAR SURGERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY VASCULAR SURGERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY VASCULAR SURGERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY VASCULAR SURGERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY LIVER CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY LIVER CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY LIVER CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY LIVER CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY LIVER CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY OPHTHALMOLOGY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY OPHTHALMOLOGY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY OPHTHALMOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY OPHTHALMOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY OPHTHALMOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY OPHTHALMOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY CATARACT TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY CATARACT TREATMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY CATARACT TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY CATARACT TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY CATARACT TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY CATARACT TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY GLAUCOMA TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY GLAUCOMA TREATMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY GLAUCOMA TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY GLAUCOMA TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY GLAUCOMA TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY GLAUCOMA TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY RETINAL THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY RETINAL THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY RETINAL THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY RETINAL THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY RETINAL THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY RETINAL THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY BACK PAIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY BACK PAIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY BACK PAIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY BACK PAIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY BACK PAIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY BACK PAIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY JOINT PAIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY JOINT PAIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY JOINT PAIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY JOINT PAIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY JOINT PAIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY JOINT PAIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MUSCULOSKELETAL PAIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MUSCULOSKELETAL PAIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MUSCULOSKELETAL PAIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MUSCULOSKELETAL PAIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MUSCULOSKELETAL PAIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MUSCULOSKELETAL PAIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PHYSIOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PHYSIOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PHYSIOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PHYSIOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PHYSIOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PHYSIOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PHYSIOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PHYSIOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MUSCLE STIMULATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MUSCLE STIMULATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MUSCLE STIMULATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MUSCLE STIMULATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MUSCLE STIMULATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MUSCLE STIMULATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY REHABILITATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY REHABILITATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY REHABILITATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY REHABILITATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY REHABILITATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 296. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY REHABILITATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 297. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY SWELLING REDUCTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 298. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY SWELLING REDUCTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 299. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY SWELLING REDUCTION, BY GROUP, 2018-2024 (USD MILLION)